InvestSMART

Truscreen Group Limited (ASX:TRU)

ALERT: Price-sensitive ASX Announcement for TRU
Current share price for TRU : $0.013 -0.002 (-13.33%)+
Announcement
Release
12 Jun 2026 7:30AM
Price at Release
$0.015
Full Release
download
Summary
TruScreen Group Limited, a leader in AI-enabled cervical cancer screening, has released a Milestone Markets Update on their activities. The company is making strides in market expansions, regulatory approvals, and collaborative partnerships across multiple regions including Africa, Asia, and Europe. Highlights include a significant study in China validating the efficacy of TruScreen's technology over traditional methods, expected regulatory approvals in India, and strategic grant applications to fund public screening programs potentially adding significant annual revenue. TruScreen is well placed to meet global screening targets set by the WHO, emphasizing its commitment to addressing cervical cancer in underserved markets.
Key Points
  • Chinese Society of Colposcopy and Cervical Pathology (CSCCP) to issue Expert Consensus on TruScreen.
  • India regulatory approval expected in 3-6 months.
  • Three UNITAID applications may add NZ$4m to annual revenue from FY2028 to FY2030.
  • Preparation underway for 10,000 women TruScreen Ultra screening programs in Zimbabwe for FY2027.
  • Uzbekistan pilot study to commence July 2026.
  • Bill & Melinda Gates Foundation grant application for study in Nigeria.
  • Rapid market expansion with distributor appointments in Asia, Africa, and Europe.
  • TruScreen’s technology validated as a superior screening tool in China.
  • Collaborations with NGOs for meeting WHO screening targets by 2030.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.